Cempra, Inc. (CEMP)

Lifshitz & Miller announces investigation on behalf of CEMP investors concerning whether CEMP adequately disclosed the safety risks of CEMP's drug solithromycin for hepatotoxicity.

If you are a CEMP investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.